[CLS] O
to O
##rsa X
##de X
de O
point O
##es X
vent O
##ric X
##ular X
ta O
##chy X
##card X
##ia X
during O
low O
dose O
intermittent O
do B
##but X
##amine X
treatment O
in O
a O
patient O
with O
di O
##lated X
card O
##io X
##my X
##op X
##athy X
and O
con O
##ges X
##tive X
heart O
failure O
. O
[SEP] O
[CLS] O
the O
authors O
describe O
the O
case O
of O
a O
56 O
- O
year O
- O
old O
woman O
with O
chronic O
, O
severe O
heart O
failure O
secondary O
to O
di O
##lated X
card O
##io X
##my X
##op X
##athy X
and O
absence O
of O
significant O
vent O
##ric X
##ular X
a O
##rr X
##hy X
##th X
##mia X
##s X
who O
developed O
q O
##t X
pro O
##long X
##ation X
and O
to O
##rsa X
##de X
de O
point O
##es X
vent O
##ric X
##ular X
ta O
##chy X
##card X
##ia X
during O
one O
cycle O
of O
intermittent O
low O
dose O
( O
2 O
. O
5 O
m O
##c X
##g X
/ O
kg O
per O
min O
) O
do B
##but X
##amine X
. O
[SEP] O
[CLS] O
this O
report O
of O
to O
##rsa X
##de X
de O
point O
##es X
vent O
##ric X
##ular X
ta O
##chy X
##card X
##ia X
during O
intermittent O
do B
##but X
##amine X
supports O
the O
hypothesis O
that O
unpredictable O
fatal O
a O
##rr X
##hy X
##th X
##mia X
##s X
may O
occur O
even O
with O
low O
doses O
and O
in O
patients O
with O
no O
history O
of O
significant O
rhythm O
disturbance O
##s X
. O
[SEP] O
[CLS] O
the O
mechanisms O
of O
pro O
##ar X
##r X
##hy X
##th X
##mic X
effects O
of O
dub B
##uta X
##mine X
are O
discussed O
. O
[SEP] O
[CLS] O
positive O
skin O
tests O
in O
late O
reactions O
to O
radio O
##graphic X
contrast B
media I
. O
[SEP] O
[CLS] O
in O
the O
last O
few O
years O
delayed O
reactions O
several O
hours O
after O
the O
injection O
of O
radio O
##graphic X
and O
contrast O
materials O
( O
p O
##rc X
) O
have O
been O
described O
with O
increasing O
frequency O
. O
[SEP] O
[CLS] O
the O
authors O
report O
two O
observations O
on O
patients O
with O
delayed O
reactions O
in O
whom O
in O
##tra X
##der X
##more X
##actions X
( O
id O
##r X
) O
and O
patch O
tests O
to O
a O
series O
of O
ion O
##ic X
and O
non O
ion O
##ic X
p O
##rc X
were O
studied O
. O
[SEP] O
[CLS] O
after O
an O
##gio X
##graphy X
by O
the O
ve O
##nous X
route O
in O
patient O
n O
degree O
1 O
a O
bi O
##pha X
##si X
##c X
reaction O
with O
an O
immediate O
reaction O
( O
d O
##ys X
##p X
##nea X
, O
loss O
of O
consciousness O
) O
and O
delayed O
mac O
##ro X
- O
p O
##ap X
##ular X
r O
##ash X
appeared O
, O
whilst O
patient O
n O
degree O
2 O
developed O
a O
general O
##ised X
sensation O
of O
heat O
, O
persistent O
pain O
at O
the O
site O
of O
injection O
immediately O
and O
a O
general O
##ised X
mac O
##ro X
- O
p O
##ap X
##ular X
reaction O
after O
24 O
hours O
. O
[SEP] O
[CLS] O
the O
skin O
tests O
revealed O
positive O
delayed O
reactions O
of O
24 O
hours O
and O
48 O
hours O
by O
id O
##r X
and O
patch O
tests O
to O
only O
some O
p O
##rc X
with O
common O
chains O
in O
their O
structures O
. O
[SEP] O
[CLS] O
the O
positive O
skin O
tests O
are O
in O
favour O
of O
im O
##mu X
##nological X
reactions O
and O
may O
help O
in O
diagnosis O
of O
all O
##er X
##gy X
in O
the O
patients O
. O
[SEP] O
[CLS] O
risk O
of O
trans O
##ient X
h O
##yper X
##am X
##mon X
##em X
##ic X
en O
##ce X
##pha X
##lop X
##athy X
in O
cancer O
patients O
who O
received O
continuous O
in O
##fusion X
of O
5 B
- I
flu I
##oro X
##ura X
##ci X
##l X
with O
the O
com O
##plication X
of O
de O
##hy X
##dra X
##tion X
and O
infection O
. O
[SEP] O
[CLS] O
from O
1986 O
to O
1998 O
, O
29 O
cancer O
patients O
who O
had O
32 O
episodes O
of O
trans O
##ient X
h O
##yper X
##am X
##mon X
##em X
##ic X
en O
##ce X
##pha X
##lop X
##athy X
related O
to O
continuous O
in O
##fusion X
of O
5 B
- I
flu I
##oro X
##ura X
##ci X
##l X
( O
5 B
- I
f I
##u X
) O
were O
identified O
. O
[SEP] O
[CLS] O
none O
of O
the O
patients O
had O
de O
##com X
##pen X
##sat X
##ed X
liver O
disease O
. O
[SEP] O
[CLS] O
onset O
of O
h O
##yper X
##am X
##mon X
##em X
##ic X
en O
##ce X
##pha X
##lop X
##athy X
varied O
from O
0 O
. O
5 O
to O
5 O
days O
( O
mean O
: O
2 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
days O
) O
after O
the O
initiation O
of O
ch O
##em X
##otherapy X
. O
[SEP] O
[CLS] [CLS]
plasma O
am B
##mon X
##ium X
level O
ranged O
from O
248 O
to O
238 O
##7 X
micro O
##g X
% O
( O
mean O
: O
62 O
##6 X
+ O
/ O
- O
43 O
##1 X
micro O
##g X
% O
) O
. O
[SEP] O
[CLS] O
among O
the O
32 O
episodes O
, O
26 O
( O
81 O
% O
) O
had O
various O
degrees O
of O
a O
##zo X
##tem X
##ia X
, O
18 O
( O
56 O
% O
) O
occurred O
during O
bacterial O
infections O
and O
14 O
( O
44 O
% O
) O
without O
infection O
occurred O
during O
periods O
of O
de O
##hy X
##dra X
##tion X
. O
[SEP] O
[CLS] O
higher O
plasma O
am B
##mon X
##ium X
levels O
and O
more O
rapid O
onset O
of O
h O
##yper X
##am X
##mon X
##emia X
were O
seen O
in O
18 O
patients O
with O
bacterial O
infections O
( O
p O
= O
0 O
. O
00 O
##3 X
and O
0 O
. O
000 O
##6 X
, O
respectively O
) O
and O
in O
nine O
patients O
receiving O
high O
daily O
doses O
( O
260 O
##0 X
or O
1800 O
mg O
/ O
m O
##2 X
) O
of O
5 B
- I
f I
##u X
( O
p O
= O
0 O
. O
000 O
##1 X
and O
< O
0 O
. O
000 O
##1 X
, O
respectively O
) O
. O
[SEP] O
[CLS] O
in O
25 O
out O
of O
32 O
episodes O
( O
78 O
% O
) O
, O
plasma O
am B
##mon X
##ium X
levels O
and O
mental O
status O
returned O
to O
normal O
within O
2 O
days O
after O
adequate O
management O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
h O
##yper X
##am X
##mon X
##em X
##ic X
en O
##ce X
##pha X
##lop X
##athy X
can O
occur O
in O
patients O
receiving O
continuous O
in O
##fusion X
of O
5 B
- I
f I
##u X
. O
[SEP] O
[CLS] [CLS]
a O
##zo X
##tem X
##ia X
, O
body O
fluid O
ins O
##uff X
##iciency X
and O
bacterial O
infections O
were O
frequently O
found O
in O
these O
patients O
. O
[SEP] O
[CLS] O
it O
is O
therefore O
important O
to O
recognize O
this O
condition O
in O
patients O
receiving O
continuous O
in O
##fusion X
of O
5 B
- I
f I
##u X
. O
[SEP] O
[CLS] O
the O
effects O
of O
q B
##uin X
##ine X
and O
4 B
- I
amino I
##py X
##rid X
##ine X
on O
conditioned O
place O
preference O
and O
changes O
in O
motor O
activity O
induced O
by O
m O
##or X
##phine X
in O
rats O
. O
[SEP] O
[CLS] O
1 O
. O
[SEP] O
[CLS] O
the O
effects O
of O
two O
un O
##sel X
##ec X
##tive X
potassium B
( O
k O
( O
+ O
) O
- O
) O
channel O
block O
##ers X
, O
q B
##uin X
##ine X
( O
12 O
. O
5 O
, O
25 O
and O
50 O
mg O
/ O
kg O
) O
and O
4 B
- I
amino I
##py X
##rid X
##ine X
( O
1 O
and O
2 O
mg O
/ O
kg O
) O
, O
on O
conditioned O
place O
preference O
and O
bi O
##pha X
##si X
##c X
changes O
in O
motor O
activity O
induced O
by O
m B
##or X
##phine X
( O
10 O
mg O
/ O
kg O
) O
were O
tested O
in O
w O
##ista X
##r X
rats O
. O
[SEP] O
[CLS] O
q B
##uin X
##ine X
is O
known O
to O
block O
voltage O
- O
, O
calcium B
- O
and O
at O
##p X
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
while O
4 B
- I
amino I
##py X
##rid X
##ine X
is O
known O
to O
block O
voltage O
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
. O
[SEP] O
[CLS] O
2 O
. O
[SEP] O
[CLS] O
in O
the O
counter O
##bal X
##ance X
##d X
method O
, O
q B
##uin X
##ine X
at O
##ten X
##uated O
m B
##or X
##phine X
- O
induced O
place O
preference O
, O
whereas O
4 B
- I
amino I
##py X
##rid X
##ine X
was O
ineffective O
. O
[SEP] O
[CLS] O
in O
the O
motor O
activity O
test O
measured O
with O
an O
anime O
##x X
- O
activity O
meter O
neither O
of O
the O
k O
( O
+ O
) O
- O
channel O
block O
##ers X
affected O
m B
##or X
##phine X
- O
induced O
h O
##y X
##po X
##act X
##ivity X
, O
but O
both O
k O
( O
+ O
) O
- O
channel O
block O
##ers X
prevented O
m B
##or X
##phine X
- O
induced O
secondary O
h O
##yper X
##act X
##ivity X
. O
[SEP] O
[CLS] O
3 O
. O
[SEP] O
[CLS] O
these O
results O
suggest O
the O
involvement O
of O
q B
##uin X
##ine X
- O
sensitive O
but O
not O
4 B
- I
amino I
##py X
##rid X
##ine X
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
in O
m B
##or X
##phine X
reward O
. O
[SEP] O
[CLS] O
it O
is O
also O
suggested O
that O
the O
blockade O
of O
k O
( O
+ O
) O
- O
channels O
sensitive O
to O
these O
block O
##ers X
is O
not O
sufficient O
to O
prevent O
m B
##or X
##phine X
- O
induced O
h O
##y X
##po X
##act X
##ivity X
whereas O
m B
##or X
##phine X
- O
induced O
h O
##yper X
##act X
##ivity X
seems O
to O
be O
connected O
to O
both O
q B
##uin X
##ine X
- O
and O
4 B
- I
amino I
##py X
##rid X
##ine X
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
. O
[SEP] O
[CLS] O
no O
##ci X
##ce X
##pt X
##in X
/ O
orphan O
##in X
f O
##q X
and O
no O
##cist X
##ati X
##n X
on O
learning O
and O
memory O
imp O
##air X
##ment X
induced O
by O
s B
##co X
##pol X
##amine X
in O
mice O
. O
[SEP] O
[CLS] O
1 O
. O
[SEP] O
[CLS] O
no O
##ci X
##ce X
##pt X
##in X
, O
also O
known O
as O
orphan O
##in X
f O
##q X
, O
is O
an O
end O
##ogen X
##ous X
l O
##igan X
##d X
for O
the O
orphan O
op O
##io X
##id X
receptor O
- O
like O
receptor O
1 O
( O
or O
##l X
##1 X
) O
and O
involves O
in O
various O
functions O
in O
the O
central O
nervous O
system O
( O
c O
##ns X
) O
. O
[SEP] O
[CLS] O
on O
the O
other O
hand O
, O
no O
##cist X
##ati X
##n X
is O
recently O
isolated O
from O
the O
same O
precursor O
as O
no B
##ci X
##ce X
##pt X
##in X
and O
blocks O
no B
##ci X
##ce X
##pt X
##in X
- O
induced O
all O
##ody X
##nia X
and O
h O
##yper X
##al X
##ges X
##ia X
. O
[SEP] O
[CLS] O
2 O
. O
[SEP] O
[CLS] O
although O
or O
##l X
##1 X
receptors O
which O
display O
a O
high O
degree O
of O
sequence O
ho O
##mology X
with O
classical O
op O
##io X
##id X
receptors O
are O
abundant O
in O
the O
hip O
##po X
##cam X
##pus X
, O
little O
is O
known O
regarding O
their O
role O
in O
learning O
and O
memory O
. O
[SEP] O
[CLS] O
3 O
. O
[SEP] O
[CLS] O
the O
present O
study O
was O
designed O
to O
investigate O
whether O
no O
##ci X
##ce X
##pt X
##in X
/ O
orphan O
##in X
f O
##q X
and O
no O
##cist X
##ati X
##n X
could O
m O
##od X
##ulate X
imp O
##air X
##ment X
of O
learning O
and O
memory O
induced O
by O
s B
##co X
##pol X
##amine X
, O
a O
m O
##us X
##car X
##ini X
##c X
ch O
##olin X
##ergic X
receptor O
antagonist O
, O
using O
spontaneous O
alter O
##nation X
of O
y O
- O
maze O
and O
step O
- O
down O
type O
passive O
avoid O
##ance X
tasks O
in O
mice O
. O
[SEP] O
[CLS] O
4 O
. O
[SEP] O
[CLS] O
while O
no O
##cist X
##ati X
##n X
( O
0 O
. O
5 O
- O
5 O
. O
0 O
nm O
##ol X
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
administered O
30 O
min O
before O
spontaneous O
alter O
##nation X
performance O
or O
the O
training O
session O
of O
the O
passive O
avoid O
##ance X
task O
, O
had O
no O
effect O
on O
spontaneous O
alter O
##nation X
or O
passive O
avoid O
##ance X
behaviour O
##s X
, O
a O
lower O
per O
cent O
alter O
##nation X
and O
shorter O
median O
step O
- O
down O
late O
##ncy X
in O
the O
retention O
test O
were O
obtained O
in O
no B
##ci X
##ce X
##pt X
##in X
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nm O
##ol X
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
- O
treated O
normal O
mice O
. O
[SEP] O
[CLS] O
5 O
. O
[SEP] O
[CLS] O
administration O
of O
no O
##cist X
##ati X
##n X
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nm O
##ol X
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
30 O
min O
before O
spontaneous O
alter O
##nation X
performance O
or O
the O
training O
session O
of O
the O
passive O
avoid O
##ance X
task O
, O
at O
##ten X
##uated X
the O
s B
##co X
##pol X
##amine X
- O
induced O
imp O
##air X
##ment X
of O
spontaneous O
alter O
##nation X
and O
passive O
avoid O
##ance X
behaviour O
##s X
. O
[SEP] O
[CLS] O
6 O
. O
[SEP] O
[CLS] O
these O
results O
indicated O
that O
no O
##cist X
##ati X
##n X
, O
a O
new O
biological O
##ly X
active O
p O
##eptide X
, O
am O
##eli X
##ora X
##tes X
imp O
##air X
##ments X
of O
spontaneous O
alter O
##nation X
and O
passive O
avoid O
##ance X
induced O
by O
s B
##co X
##pol X
##amine X
, O
and O
suggested O
that O
these O
p O
##eptide X
##s X
play O
opposite O
roles O
in O
learning O
and O
memory O
. O
[SEP] O
[CLS] O
me O
##lo X
##xi X
##cam X
- O
induced O
liver O
toxicity O
. O
[SEP] O
[CLS] [PAD]
we O
report O
the O
case O
of O
a O
female O
patient O
with O
r O
##he X
##uma X
##to X
##id X
art O
##hr X
##itis X
who O
developed O
acute O
c O
##yt X
##oly X
##tic X
he O
##pa X
##titis X
due O
to O
me B
##lo X
##xi X
##cam X
. O
[SEP] O
[CLS] O
recently O
introduced O
in O
be B
##l X
##gi X
##um X
, O
me B
##lo X
##xi X
##cam X
is O
the O
first O
non O
##ster X
##oid X
##al X
anti O
##in X
##f X
##lam X
##mat X
##ory X
drug O
with O
selective O
action O
on O
the O
in O
##du X
##cible X
form O
of O
c O
##y X
##c X
##lo X
##ox X
##y X
##gen X
##ase X
2 O
. O
[SEP] O
[CLS] O
the O
acute O
c O
##yt X
##oly X
##tic X
he O
##pa X
##titis X
occurred O
rapidly O
after O
me B
##lo X
##xi X
##cam X
administration O
and O
was O
associated O
with O
the O
development O
of O
anti O
##nu X
##cle X
##ar X
antibodies O
suggesting O
a O
h O
##yper X
##sen X
##si X
##ti X
##vity X
mechanism O
. O
[SEP] O
[CLS] O
this O
first O
case O
of O
me B
##lo X
##xi X
##cam X
related O
liver O
toxicity O
demonstrates O
the O
potential O
of O
this O
drug O
to O
induce O
he O
##pa X
##tic X
damage O
. O
[SEP] O
[CLS] O
induction O
of O
a O
##pop X
##tosis X
by O
re B
##mo X
##xi X
##p X
##ride X
meta O
##bol X
##ites X
in O
h O
##l X
##60 X
and O
c O
##d X
##34 X
+ O
/ O
c O
##d X
##19 X
- O
human O
bone O
ma O
##rrow X
pro O
##gen X
##itor X
cells O
: O
potential O
relevance O
to O
re B
##mo X
##xi X
##p X
##ride X
- O
induced O
a O
##p X
##lastic X
an O
##emia X
. O
[SEP] O
